Literature DB >> 6466518

Effects of vasodilator treatment with felodipine on haemodynamic responses to treadmill exercise in congestive heart failure.

A D Timmis, P Smyth, J F Kenny, S Campbell, D E Jewitt.   

Abstract

Treatment with vasodilators in heart failure has not always produced a useful improvement in the haemodynamic responses to exercise, and in many cases early drug tolerance has further limited the potential of this type of treatment. In a study to evaluate the efficacy of felodipine, a new calcium antagonist with selective vasodilator properties, in the management of congestive heart failure 10 patients with congestive heart failure underwent treadmill exercise testing before and during oral treatment with felodipine 30 mg daily. At every level of exercise felodipine lowered the pulmonary capillary wedge pressure, whereas cardiac index and stroke index increased considerably. The haemodynamic improvement was associated with an increase in the duration of exercise to exhaustion. Importantly, these beneficial effects were sustained throughout four weeks of treatment without evidence of drug tolerance. These observations suggest a useful role for felodipine in the long term management of congestive heart failure.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6466518      PMCID: PMC481631          DOI: 10.1136/hrt.52.3.314

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  26 in total

1.  Proceedings of the british cardiac society.

Authors: 
Journal:  Br Heart J       Date:  1984-01

Review 2.  Specific pharmacology of calcium in myocardium, cardiac pacemakers, and vascular smooth muscle.

Authors:  A Fleckenstein
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

3.  Acute hemodynamic responses to sublingual nifedipine: dependence on left ventricular function.

Authors:  P A Ludbrook; A J Tiefenbrunn; F R Reed; B E Sobel
Journal:  Circulation       Date:  1982-03       Impact factor: 29.690

4.  Interaction of the antihypertensive drug felodipine with calmodulin.

Authors:  S L Bostróm; B Ljung; S Mårdh; S Forsen; E Thulin
Journal:  Nature       Date:  1981-08-20       Impact factor: 49.962

5.  Unpredictable response to nifedipine in severe cardiac failure.

Authors:  N Brooks; M Cattell; J Pidgeon; R Balcon
Journal:  Br Med J       Date:  1980-11-15

6.  Marked early attenuation of hemodynamic effects of oral prazosin therapy in chronic congestive heart failure.

Authors:  U Elkayam; T H Lejemtel; M Mathur; H S Ribner; W H Frishman; J Strom; E H Sonnenblick
Journal:  Am J Cardiol       Date:  1979-09       Impact factor: 2.778

7.  Rest and exercise hemodynamic effects of oral hydralazine in patients with coronary artery disease and left ventricular dysfunction.

Authors:  M C Hindman; D A Slosky; R H Peter; G E Newman; R H Jones; A G Wallace
Journal:  Circulation       Date:  1980-04       Impact factor: 29.690

8.  Immediate effects of hydralazine-isosorbide dinitrate combination on exercise capacity and exercise hemodynamics in patients with left ventricular failure.

Authors:  J A Franciosa; J N Cohn
Journal:  Circulation       Date:  1979-06       Impact factor: 29.690

9.  Hydralazine in the long-term treatment of chronic heart failure: lack of difference from placebo.

Authors:  J A Franciosa; K T Weber; T B Levine; G T Kinasewitz; J S Janicki; J West; M M Henis; J N Cohn
Journal:  Am Heart J       Date:  1982-09       Impact factor: 4.749

10.  Sustained effectiveness of chronic prazosin therapy in severe chronic congestive heart failure.

Authors:  O Bertel; F Burkart; F R Bühler
Journal:  Am Heart J       Date:  1981-05       Impact factor: 4.749

View more
  21 in total

Review 1.  Calcium antagonists in patients with heart failure. A review.

Authors:  H Reicher-Reiss; E Barasch
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

2.  The search of an ideal oral positive inotropic agent.

Authors:  L B Tan
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  Felodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.

Authors:  E Saltiel; A G Ellrodt; J P Monk; M S Langley
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

Review 4.  Medical treatment beyond ACE inhibition: false promise or lack of vision?

Authors:  J T Walsh; A J Cowley
Journal:  Br Heart J       Date:  1994-09

Review 5.  'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Authors:  D D Freedman; D D Waters
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

6.  Milrinone in heart failure. Effects on exercise haemodynamics during short term treatment.

Authors:  A D Timmis; P Smyth; D E Jewitt
Journal:  Br Heart J       Date:  1985-07

7.  [Calcium antagonists in heart failure?].

Authors:  H Drexler; H Just
Journal:  Klin Wochenschr       Date:  1986-10-15

Review 8.  Felodipine clinical pharmacokinetics.

Authors:  P H Dunselman; B Edgar
Journal:  Clin Pharmacokinet       Date:  1991-12       Impact factor: 6.447

9.  Felodipine in patients with chronic heart failure: discrepant haemodynamic and clinical effects.

Authors:  L B Tan; R G Murray; W A Littler
Journal:  Br Heart J       Date:  1987-08

10.  Acute and chronic effects of the dihydropyridine calcium antagonist nisoldipine on the resting and exercise hemodynamics, neurohumoral parameters, and functional capacity of patients with chronic heart failure.

Authors:  L Dei Cas; M Metra; R Ferrari; O Visioli
Journal:  Cardiovasc Drugs Ther       Date:  1993-02       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.